Retinitis Pigmentosa
Conditions
Brief summary
The aim of this study is to determine whether 9-cis-beta Caroten rich D. Brdawiil extract is effective in the treatment of retinitis pigmentosa in adolescent patients.
Detailed description
Retinitis pigmentosa is a genetically disease consisting of progressive retinal degeneration starting in the rods. Its prevalence is 1:4000 people and is the fourth most common blinding disease in Israel in 2004 \[7% of all blindness\]. The investigators treated a non-progressive form of the disease \[Fundus Albipunctatus\] by oral therapy of the food supplement made from alga Dunaliella Bardawil composed of approximately 50% 9-cis β-carotene. The 9-cis β -carotene has been shown to be a precursor of 9-cis retinoic acid both in-vitro in human intestinal mucosa and in-vivo in a ferret, perfused with 9-cis b-carotene. The night vision, as measured objectively by electroretinography (ERG) more than doubled in six patients tested following treatment. The visual field was also improved significantly. In a more recent study the investigators treated 29 retinitis pigmentosa patients with the 9-cis b Carotene algae Dunaliella Bardawil in a double masked placebo control cross over trial. Significant improvement in retinal function was recorded in 34% of the patients. As a natural extension of this study we will perform a double-masked, randomized, crossover, placebo-controlled study for adolescent patients. Longer treatment duration will be tested: a 24 week treatment with either the 9-cis β-carotene-rich capsules or placebo followed by an additional a 24 week treatment with the other capsules and a wash-out period of 24 weeks between this two type of treatments. We predict that with this study design a maximal/increased therapeutic effect as well as efficient washout will be achieved.
Interventions
DIETARY_SUPPLEMENTAlga Dunaliella Bardawil powder
9 cis beta carotene rich Alga Dunaliella Bardawil powder
DIETARY_SUPPLEMENTPlacebo:Starch
Starch powder
Sponsors
Sheba Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
12 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* Written informed consent to participate in the study. * Adolescent 12-18 years old. * Electroretinogram (ERG) responses compatible with the diagnosis of Retinitis Pigmentosa
Exclusion criteria
* Currently a smoker * Current use of vitamin A/ β-carotene supplements * Active arterial disease within 3 months prior to enrolment in the study, e.g. unstable angina, myocardial infarction, transient ischemic attack, stroke, coronary artery bypass graft surgery * History of malignancy, excepting basal or squamous cell skin carcinoma * Females who are pregnant, or breast feeding, or are premenopausal but not using chemical or mechanical contraception * Uncontrolled hypertension, defined either as resting diastolic blood pressure \>95 mmHg (taken from the mean of 3 readings) or as resting systolic blood pressure \>180 mmHg * History of alcohol abuse or drug abuse or both * Intention to engage in vigorous exercise or an aggressive diet regimen * Uncontrolled endocrine or metabolic disease * Participation in another investigational drug study within 4 weeks prior to enrolment * Serious or unstable medical or psychological condition which, in the opinion of the PI, would compromise the subject's safety or successful participation in the study * Initiation of hormone replacement therapy or oral contraceptive therapy within 3 months prior to enrolment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean binocular maximal scotopic electroretinogram b-wave response | up to weeks 72 | Using the protocol of the International Society for Clinical Electrophysiology of Vision and the UTAS 3000 system (LKC Technologies, Gaithersburg, MD), full-field electroretinographic responses will be recorded from both eyes of each patient. For scotopic conditions, maximal ERG b-wave responses will be recorded following 30 minutes of dark adaptation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The area within the Dark adapted chromatic Goldamann Visual field in isopters in cm2 | On weeks 0, 24, 48, 72 | Kinetic visual field for chromatic stimuli will be recorded in both eyes after 30 minutes of dark adaptation. Area of vision within the isopter will be measured by software in cm2. |
| The area within Goldamann Visual field in isopters in cm2 | On weeks 0, 24, 48, 72 | Kinetic visual field will be recorded in both eyes. Area of vision within the isopter will be measured by software in cm2. |
| Mean binocular maximal photopic electroretinogram b-wave response | On weeks 0, 24, 48, 72 | Using the protocol of the International Society for Clinical Electrophysiology of Vision and the UTAS 3000 system (LKC Technologies, Gaithersburg, MD), full-field photopic electroretinographic responses will be recorded from both eyes of each patient. |
| Best-corrected visual acuity (EDTRS) | On weeks 0, 24, 48, 72 | — |
| Objective visual field by chromatic multifocal pupillometer | On weeks 0,24,48,72 | — |
Countries
Israel
Contacts
Primary ContactYgal Rotenstreich, MD
Outcome results
None listed